Get the Stockscreener App
16.18
0.84%
0.135
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $16.18, with a volume of 1.81M.
It is up +0.84% in the last 24 hours and down -0.83% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$16.04
Open:
$15.902
24h Volume:
1.81M
Relative Volume:
0.18
Market Cap:
$18.58B
Revenue:
$14.57B
Net Income/Loss:
$-296.50M
P/E Ratio:
-62.45
EPS:
-0.259
Net Cash Flow:
$1.64B
1W Performance:
-1.55%
1M Performance:
-0.83%
6M Performance:
+2.57%
1Y Performance:
+51.31%
1-Day Range:
$15.88
$16.20
1-Week Range:
$15.88
$16.71
52-Week Range:
$9.425
$18.39
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.18 | 18.49B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
17.59 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.705 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.40 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.67 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.71 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris Inc. (VTRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc - Stock Titan
ETFs Investing in Viatris, Inc. Stocks - TradingView
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView
Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run - Sahm
Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash - TradingView
Why Viatris (VTRS) Is Down 6.4% After Boosting Guidance And Completing A $1.15 Billion Buyback - simplywall.st
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program - Yahoo Finance
Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval - Yahoo Finance
Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress - Yahoo Finance
Viatris Inc. (VTRS) Stock Forecasts - Yahoo! Finance Canada
Viatris (VTRS) Stock Looks Stuck Between Higher Guidance And Wider Losses - Sahm
Viatris Inc. (US92556V1061.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris Inc. Stock Sheds 7.7%, Underperforms Market - webull.com
Viatris Earnings: Good Performance in Key Regions and Outlook Increase Make for a Solid Quarter - Morningstar
Harrow Enters Agreement to Acquire Tyrvaya Dry Eye Treatment From Viatris Inc. - VisionMonday.com
Viatris Inc. Stock 12‑Month Price Target Raised to $18.71, Implies 6% Upside - TradingView
Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ... - Yahoo Finance
Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overv - GuruFocus
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Inc Q2 2026: Revenue $3.76B, EPS $(0.10) — 10-Q Summary - TradingView
Viatris (NASDAQ: VTRS) swings to H1 2026 profit as revenue tops $7.27B - Stock Titan
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022. - marketscreener.com
Viatris Q2 2026 slides: strong beat, raised outlook, H2 headwinds - Investing.com
Viatris Q2 2026 slides: strong results lift guidance amid H2 headwinds - Investing.com
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook - TradingView
Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth - Morningstar
Viatris Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:VTRS) 2026-08-06 - Seeking Alpha
Viatris stock hits 52-week high at 18.27 USD - Investing.com
Viatris Q2 2026 slides: strong beat drives guidance raise - Investing.com
FMR LLC discloses 8.3% Viatris Inc (VTRS) ownership, over 96M shares - Stock Titan
Earnings call transcript: Viatris tops Q2 2026 estimates, lifts outlook - Investing.com
Viatris Announces Quarterly Dividend - marketscreener.com
Viatris Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Viatris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
VIATRIS INC (VTRS.VI) Q2 FY2026 earnings call transcript - Yahoo Finance
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Viatris' Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance - marketscreener.com
(VTRS) Viatris Expects 2026 Revenue Range $14.55B$14.95B, vs. FactSet Est of $14.79B - marketscreener.com
(VTRS) Viatris Expects 2026 Adjusted EPS Range $2.45$2.59, vs. FactSet Est of $2.45 - marketscreener.com
Viatris raises annual profit forecast on branded drug strength - marketscreener.com
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026 - Yahoo Finance
Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M - Seeking Alpha
Earnings Flash (VTRS) Viatris Inc. Reports Q2 Revenue $3.76B, vs. FactSet Est of $3.68B - marketscreener.com
Earnings Flash (VTRS) Viatris Inc. Posts Q2 Adjusted EPS $0.69 per Share, vs. FactSet Est of $0.60 - marketscreener.com
Viatris: Q2 Earnings Snapshot - Barchart.com
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Reports Second-Quarter 2026 Financial Results - TradingView
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):